On November 1, 2022, the Centers for Medicare & Medicaid Services (CMS) released its final rule for the calendar year (CY) 2023 Medicare Physician Fee Schedule and updates to the Quality Payment Program. CMS also released its final rule for the CY 2023 Hospital Outpatient Prospective Payment System the same day. The Association for Clinical Oncology (ASCO) is still assessing the rules, but based on a preliminary analysis, key provisions for the cancer care community are included here.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
In July 2022, ASCO and the African Organisation for Research and Training in Cancer (AORTIC) signed a memorandum of understanding committing the two organizations to collaborate to advance cancer research in Africa.
ASCO is continuing to collaborate with State Affiliates and outside stakeholders to raise awareness and facilitate implementation of the CLINICAL TREATMENT Act, which requires all states and territories to cover and reimburse routine costs of care for treating a Medicaid enrollee who is participating in a qualifying clinical trial.
The U.S. House of Representatives passed its comprehensive legislation to reauthorize the Food and Drug Administration (FDA) user fee agreements, including the Prescription Drug User Fee Act (PDUFA), the Generic Drug User Fee Act (GDUFA), the Biosimilar User Fee Act (BsUFA), and the Medical Device User Fee Act (MDUFA). ASCO is pleased that several of the Association’s priorities were included in the final House-passed bill.
From June 10-15, delegates from the Association for Clinical Oncology (ASCO) participated in the 2022 Annual Meeting of the American Medical Association’s (AMA) House of Delegates (HOD). The AMA HOD is the principal policy-making body of AMA and meets twice a year to discuss pressing issues and establish association policies. This year, the meeting returned to an in-person format in Chicago.
The AMA HOD voted to approve two ASCO-backed resolutions during the meeting:
The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) today jointly released recommendations that address the lack of equity, diversity, and inclusion (EDI) in cancer clinical trials. Published in the Journal of Clinical Oncology, “Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement” details specific actions to engage the entire cancer clinical trial ecosystem in expanding the participation of underrepresented individuals in research that advances progress against cancer.
Today, JCO Oncology Practice, a journal of the American Society of Clinical Oncology (ASCO), published a special series that examines the causes of disparities in cancer care and outcomes in the U.S. Hispanic/Latinx population and offers potential solutions to increase equity among this group. "Disparities in Cancer Care and Scientific Knowledge in Hispanic/Latinx People in the United States” features 18 articles and editorials that present new data and opportunities on a wide variety of topics, including prevention and screening, genetic testing, clinical trial enrollment and participation, access to affordable health care, and workforce representation, among others.
Proposals to reauthorize the Food and Drug Administration (FDA) user fee agreements include several ASCO priorities, including those that would increase diversity of clinical trials and strengthen the accelerated approval process.
A new article published in the American Cancer Society’s Cancer journal shares results from a national, online patient survey conducted by American Society of Clinical Oncology (ASCO), which assessed practice patterns related to weight, diet, and exercise as part of cancer care.
From April 4-8, U.S. members of the Association for Clinical Oncology (ASCO) participated in the 2022 ASCO Week of Action, which was held in conjunction with the Association’s annual Advocacy Summit. During the Week of Action, advocates from across the country sent a record 920 letters to Members of Congress through ASCO’s ACT Network urging them to take action on important policies to improve access to high-quality, equitable care for people with cancer.
President Biden’s Fiscal Year (FY) 2023 budget request includes $5 billion for the Advanced Research Projects Agency for Health (ARPA-H), the proposed new biomedical research agency focused on high-risk, bold, translational research projects. While the Association for Clinical Oncology (ASCO) strongly believes in the stated mission of ARPA-H, we are concerned that the Administration’s FY 2023 budget request invests in ARPA-H at the expense of the National Institutes of Health (NIH) and the National Cancer Institute (NCI).
Congress is considering several cancer policy priorities this week, including the PREVENT Pandemics Act, Cures 2.0, and legislation to authorize ARPA-H.
On March 17, the American Society of Clinical Oncology (ASCO) is hosting a meeting with key research stakeholders to discuss possible solutions and calls-to-action to optimize cancer clinical trials and facilitate routine patient access to trials closer to where they live.
The Association for Clinical Oncology (ASCO) is holding its annual Advocacy Summit Week of Action from April 4-8, during which ASCO members are encouraged to connect with their Members of Congress about policies and legislation that impact cancer care and research.
The National Academies of Sciences, Engineering, and Medicine (NASEM) issued a new report recommending the National Institutes of Health (NIH) implement new guidelines to standardize the collection of data on sex, gender, and sexual orientation.